Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy in Oligoprogressive HCC Following First-line PD-1 Therapy
NCT06870942Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2022
- Primary completion
- Nov 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Progression-free survival at 6 months. Started Jul 2022; status: recruiting.
Beyond the preview
Go deeper on NCT06870942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06870942.